Prognostic factors in uterine adenosarcoma: subanalysis of the SARCUT study.

adenosarcoma disease-free survival prognosis survival rate uterine neoplasms

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2024
Historique:
received: 29 02 2024
accepted: 25 04 2024
medline: 5 6 2024
pubmed: 5 6 2024
entrez: 5 6 2024
Statut: epublish

Résumé

The purpose of the study was to analyse the role of prognostic factors on the risk of recurrence and overall survival of patients with uterine adenosarcoma. A retrospective international multicentre study involving 46 centres collected 32 cases of uterine adenosarcoma, and these cases were included in the present subanalysis. Clinical and demographic features and tumour characteristics were gathered, as well as information on treatment and relapse. Disease-free and overall survival were analysed. The 5-year disease-free survival (DFS) was 85.3% and the 5-year overall survival (OS) rate was 89.5%. The risk factors significantly associated with overall survival were age (HR 1.09, 95% CI 1.03-1.15; The most significant prognostic factors in uterine adenosarcoma were age and FIGO stage and, indirectly, tumour size at diagnosis. The use of secondary surgery and/or radiotherapy could help in prolonging the disease-free status of the patients.

Identifiants

pubmed: 38835369
doi: 10.3389/fonc.2024.1393707
pmc: PMC11148341
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1393707

Informations de copyright

Copyright © 2024 Mancari, Yusuf, Macuks, Achimas-Cadariu, Piek, Sperduti, Corrado, Vizza and Zapardiel.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Auteurs

Rosanna Mancari (R)

Gynecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Yildirim Yusuf (Y)

Gynecologic Oncology Department, Tepecik Training and Research Hospital, Izmir, Türkiye.

Ronalds Macuks (R)

Latvian Oncology Center of Riga Eastern Clinical University Hospital, Riga, Latvia.

Patriciu Achimas-Cadariu (P)

Gynecologic Oncology Department, Institute of Oncology Prof. Dr. I Chiricuta, Cluj-Napoca, Romania.
Gynecologic Oncology Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj Napoca, Romania.

Jurgen Martinus Piek (JM)

Gynecologic Oncology Department, Catharina Ziekenhuis Department of Gynecology, Eindhoven, Netherlands.

Isabella Sperduti (I)

Unit of Biostatistical, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Giacomo Corrado (G)

Gynecologic Oncology Unit, Department of Woman, Child and Public Health, Fondazione Policlinico Uni-versitario A. Gemelli IRCCS, Rome, Italy.

Enrico Vizza (E)

Gynecologic Oncology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.

Ignacio Zapardiel (I)

Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain.

Classifications MeSH